Literature DB >> 17202264

Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.

Julie R McMullen1, Fatemeh Amirahmadi, Elizabeth A Woodcock, Martina Schinke-Braun, Russell D Bouwman, Kimberly A Hewitt, Janelle P Mollica, Li Zhang, Yunyu Zhang, Tetsuo Shioi, Antje Buerger, Seigo Izumo, Patrick Y Jay, Garry L Jennings.   

Abstract

Physical activity protects against cardiovascular disease, and physiological cardiac hypertrophy associated with regular exercise is usually beneficial, in marked contrast to pathological hypertrophy associated with disease. The p110alpha isoform of phosphoinositide 3-kinase (PI3K) plays a critical role in the induction of exercise-induced hypertrophy. Whether it or other genes activated in the athlete's heart might have an impact on cardiac function and survival in a setting of heart failure is unknown. To examine whether progressive exercise training and PI3K(p110alpha) activity affect survival and/or cardiac function in two models of heart disease, we subjected a transgenic mouse model of dilated cardiomyopathy (DCM) to swim training, genetically crossed cardiac-specific transgenic mice with increased or decreased PI3K(p110alpha) activity to the DCM model, and subjected PI3K(p110alpha) transgenics to acute pressure overload (ascending aortic constriction). Life-span, cardiac function, and molecular markers of pathological hypertrophy were examined. Exercise training and increased cardiac PI3K(p110alpha) activity prolonged survival in the DCM model by 15-20%. In contrast, reduced PI3K(p110alpha) activity drastically shortened lifespan by approximately 50%. Increased PI3K(p110alpha) activity had a favorable effect on cardiac function and fibrosis in the pressure-overload model and attenuated pathological growth. PI3K(p110alpha) signaling negatively regulated G protein-coupled receptor stimulated extracellular responsive kinase and Akt (via PI3K, p110gamma) activation in isolated cardiomyocytes. These findings suggest that exercise and enhanced PI3K(p110alpha) activity delay or prevent progression of heart disease, and that supraphysiologic activity can be beneficial. Identification of genes important for hypertrophy in the athlete's heart could offer new strategies for treating heart failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202264      PMCID: PMC1766433          DOI: 10.1073/pnas.0606663104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Navigating the signalling network in mouse cardiac myocytes.

Authors:  Gilberto R Sambrano; Iain Fraser; Heping Han; Yan Ni; Tim O'Connell; Zhen Yan; James T Stull
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  The conserved phosphoinositide 3-kinase pathway determines heart size in mice.

Authors:  T Shioi; P M Kang; P S Douglas; J Hampe; C M Yballe; J Lawitts; L C Cantley; S Izumo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation.

Authors:  Lazaros C Foukas; Marc Claret; Wayne Pearce; Klaus Okkenhaug; Stephen Meek; Emma Peskett; Sara Sancho; Andrew J H Smith; Dominic J Withers; Bart Vanhaesebroeck
Journal:  Nature       Date:  2006-04-12       Impact factor: 49.962

4.  Akt/protein kinase B promotes organ growth in transgenic mice.

Authors:  Tetsuo Shioi; Julie R McMullen; Peter M Kang; Pamela S Douglas; Toshiyuki Obata; Thomas F Franke; Lewis C Cantley; Seigo Izumo
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 5.  Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death.

Authors:  Orlando F Bueno; Jeffery D Molkentin
Journal:  Circ Res       Date:  2002-11-01       Impact factor: 17.367

6.  Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes.

Authors:  G G Neri Serneri; M Boddi; P A Modesti; I Cecioni; M Coppo; L Padeletti; A Michelucci; A Colella; G Galanti
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

7.  Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase.

Authors:  Antje Buerger; Olga Rozhitskaya; Megan C Sherwood; Adam L Dorfman; Egbert Bisping; E Dale Abel; William T Pu; Seigo Izumo; Patrick Y Jay
Journal:  J Card Fail       Date:  2006-06       Impact factor: 5.712

8.  Myostatin regulates cardiomyocyte growth through modulation of Akt signaling.

Authors:  Michael R Morissette; Stuart A Cook; ShiYin Foo; Godfrina McKoy; Noboru Ashida; Mikhail Novikov; Marielle Scherrer-Crosbie; Ling Li; Takashi Matsui; Gavin Brooks; Anthony Rosenzweig
Journal:  Circ Res       Date:  2006-06-08       Impact factor: 17.367

9.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Authors:  Qi-Wen Fan; Zachary A Knight; David D Goldenberg; Wei Yu; Keith E Mostov; David Stokoe; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

10.  Rapamycin attenuates load-induced cardiac hypertrophy in mice.

Authors:  Tetsuo Shioi; Julie R McMullen; Oleg Tarnavski; Kimber Converso; Megan C Sherwood; Warren J Manning; Seigo Izumo
Journal:  Circulation       Date:  2003-03-17       Impact factor: 29.690

View more
  100 in total

Review 1.  Specific PI3K isoform modulation in heart failure: lessons from transgenic mice.

Authors:  Alessandra Ghigo; Fulvio Morello; Alessia Perino; Federico Damilano; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  Exercise in hypertrophic cardiomyopathy.

Authors:  Sharlene M Day
Journal:  J Cardiovasc Transl Res       Date:  2009-10-14       Impact factor: 4.132

Review 3.  Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Cell Physiol Biochem       Date:  2015-02-11

Review 4.  Influence of Physical Activity on Hypertension and Cardiac Structure and Function.

Authors:  Sheila M Hegde; Scott D Solomon
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

Review 5.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

6.  Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy.

Authors:  Kai-Chien Yang; Nicholas C Foeger; Céline Marionneau; Patrick Y Jay; Julie R McMullen; Jeanne M Nerbonne
Journal:  J Physiol       Date:  2010-10-25       Impact factor: 5.182

7.  Myosin light chain phosphorylation is critical for adaptation to cardiac stress.

Authors:  Sonisha A Warren; Laura E Briggs; Huadong Zeng; Joyce Chuang; Eileen I Chang; Ryota Terada; Moyi Li; Maurice S Swanson; Stewart H Lecker; Monte S Willis; Francis G Spinale; Julie Maupin-Furlowe; Julie R McMullen; Richard L Moss; Hideko Kasahara
Journal:  Circulation       Date:  2012-10-24       Impact factor: 29.690

8.  Prolonged leptin treatment increases transient outward K⁺ current via upregulation of Kv4.2 and Kv4.3 channel subunits in adult rat ventricular myocytes.

Authors:  Nieves Gómez-Hurtado; María Fernández-Velasco; María Soledad Fernández-Alfonso; Lisardo Boscá; Carmen Delgado
Journal:  Pflugers Arch       Date:  2013-09-18       Impact factor: 3.657

9.  Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure.

Authors:  Masaya Tanno; Atsushi Kuno; Toshiyuki Yano; Tetsuji Miura; Shin Hisahara; Satoko Ishikawa; Kazuaki Shimamoto; Yoshiyuki Horio
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

Review 10.  Recent advances of adapter proteins in the regulation of heart diseases.

Authors:  Li Tao; Linna Jia; Yuntian Li; Chengyun Song; Zheng Chen
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.